The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)
Public ClinicalTrials.gov record NCT05543642. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The COvid19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.
Study identification
- NCT ID
- NCT05543642
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 129 participants
Conditions and interventions
Conditions
Interventions
- Hepatitis A vaccine Biological
- Diphtheria, pertussis, and tetanus booster vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 11, 2022 (Actual)
- Primary completion
- Apr 1, 2025 (Actual)
- Completion
- Aug 14, 2026 (Actual)
- Last update posted
- Sep 24, 2026
2022 – 2026
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Center for Rheumatic Diseases | Northport | Alabama | 35473 | — |
| Southwest Florida Rheumatology | Riverview | Florida | 33569 | — |
| St. Luke's Rheumatology | Boise | Idaho | 83702 | — |
| Jayashree Sinha, MD | Clovis | New Mexico | 88101 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Altoona Center for Clinical Research | Duncansville | Pennsylvania | 16635 | — |
| Cumberland Rheumatology | Crossville | Tennessee | 38555 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05543642, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05543642 live on ClinicalTrials.gov.